Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Bullboard Posts
Post by skyplton Feb 02, 2019 7:33am
476 Views
Post# 29309501

Catalysts

Catalysts A valid point was made regarding the anticipated rebuttal; any potential suitor will have likely been given access to what has been found.  The rebuttal is not a legal requirement so Aphria is not bound to withold their findings from any company doing their due diligence.  As well, now that the share price is trading above pre-short attack I would be surprised if the lawsuits get any traction.  One thing that has not been discussed is the reluctance by any major investor to be the lead plaintiff.  Most are not willing to advertise their wrong call, and others will not want to be on that US border list (bogus list, but if you recall some of the press made a big FUD deal about it).

Most here are in agreement there is some sort of offer on the way.  Though I am shy to speculate (that got many of us in trouble last Fall when we convinced ourselves the Altria deal had been done); there can be no denying that 20+ million shares traded is not retail investor action.  At some point whoever is acquiring at these levels will have to (legally) announce their intentions.  In my view that is when the stock price will rapidly climb.

Good luck to all.  At one point my 30 dollar standing sell order was a pipe dream primarily intended to possibly negate my shares being used for any sort of shorting.  It has been changed to 40; that sell order seems overly optimistic but no longer impossible dream.

A bidding war is entirely possible, especially if two companies are acquiring shares.  Like many longs here they have run the numbers and see how undervalued APHA is.  More importantly, Cronos and Tilray are acutely aware they do not have the required production to meet their obligations.

As I said earlier...5 or 40 are the silly extremes.  We already saw the one side of that spectrum, I now believe it not unrealistic to see the other.  Owning APHA has convinced me this sector does not follow normal stock trading patterns.  Time to see this stock realize its potential.


Bullboard Posts